NASDAQ$ABUS
Arbutus Biopharma Corp · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Arbutus reported its second quarter 2021 financial results and provided a corporate update.
Arbutus Biopharma Corporation reported a net loss attributable to common shares of $22.7 million ($0.23 basic and diluted loss per common share) for the three months ended June 30, 2021. The company had cash, cash equivalents and investments totaling $121.3 million as of June 30, 2021.
- Highlighted new data on AB-729 in four abstracts at the EASL International Liver Congress™.
- Announced two additional proof-of-concept clinical collaborations to evaluate AB-729 in combination with agents from Vaccitech plc and Antios Therapeutics, Inc.
- Announced FDA authorization to proceed with a Phase 2a clinical trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic HBV.
- Presented pre-clinical data for AB-836 at EASL, suggesting the potential for increased efficacy and an enhanced resistance profile.
Headline financials
Revenue & EPS history
Arbutus · Revenue · Quarterly
$2.33M
Revenue by segment
Arbutus · $689K total across 1 segment · Q2 2020
- Non-cash Royalty Revenue$689K—100.0%
Forward guidance
Arbutus expects a productive second half of 2021, including additional data from the ongoing Phase 1a/1b clinical trial with AB-729, initiation of two Phase 2a proof-of-concept clinical trials for AB-729, and initial Phase 1a/1b data from our proprietary oral capsid inhibitor, AB-836. The Company believes its cash, cash equivalents and investments of $121.3 million as of June 30, 2021 are sufficient to fund the Company’s operations through the third quarter of 2022.
Tailwinds
- Additional data from the ongoing Phase 1a/1b clinical trial with AB-729.
- Initiation of two Phase 2a proof-of-concept clinical trials for AB-729.
- Initial Phase 1a/1b data from our proprietary oral capsid inhibitor, AB-836.
- CTA filing expected in the second half of 2021.
- Another proof-of-concept clinical trial expected in early 2022.
Headwinds
- Anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated.
- Arbutus may elect to change its strategy regarding its product candidates and clinical development activities.
- Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products.
- Economic and market conditions may worsen.
- The ongoing COVID-19 pandemic could significantly disrupt Arbutus’ clinical development programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2021
-1.3%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+0.1%
Avg return
30 days after
37%
23 / 63 earnings
Positive
+22.2%
Q1 2020
Best reaction
-18.6%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +0.0% | -3.2% | — | |
| Q3 2025 | -5.8% | -8.1% | -2.7% | |
| Q2 2025 | +1.8% | -1.8% | +23.2% | |
| Q1 2025 | -0.9% | -1.9% | +10.7% | |
| Q4 2024 | -2.4% | +3.9% | -1.8% | |
| Q3 2024 | -5.8% | -5.8% | -7.1% | |
| Q2 2024 | -0.8% | -4.0% | +2.7% | |
| Q1 2024 | +0.7% | +5.6% | +24.9% | |
| Q4 2023 | -3.1% | -7.3% | -10.4% | |
| Q3 2023 | -0.5% | -5.9% | +10.6% | |
| Q2 2023 | +2.9% | -2.4% | -1.4% | |
| Q1 2023 | +3.6% | +4.0% | +2.8% | |
| Q4 2022 | +1.8% | +4.3% | +7.8% | |
| Q3 2022 | +0.8% | +7.3% | +6.1% | |
| Q2 2022 | +2.8% | +0.0% | -10.2% | |
| Q1 2022 | +1.6% | -20.5% | +8.4% | |
| Q4 2021 | -9.1% | -6.8% | -0.3% | |
| Q3 2021 | -9.6% | -9.1% | +7.8% | |
| Q2 2021 | +9.1% | +13.8% | +23.6% | |
| Q1 2021 | -15.9% | -20.2% | -11.5% | |
| Q4 2020 | -9.3% | -1.1% | -5.8% | |
| Q3 2020 | -8.8% | +5.9% | +31.0% | |
| Q2 2020 | -16.2% | -18.5% | -44.2% | |
| Q1 2020 | +22.2% | +55.6% | +37.0% | |
| Q4 2019 | -2.0% | -8.3% | -70.0% | |
| Q3 2019 | -4.0% | -3.4% | +53.7% | |
| Q2 2019 | +1.2% | +1.2% | -11.0% | |
| Q1 2019 | -5.4% | -10.0% | -36.4% | |
| Q4 2018 | -8.0% | +2.7% | +9.5% | |
| Q3 2018 | +13.7% | -6.7% | -7.4% | |
| Q2 2018 | -18.6% | -19.4% | -23.2% | |
| Q1 2018 | +3.5% | +8.8% | +7.0% | |
| Q4 2017 | -12.5% | -17.5% | -13.3% | |
| Q3 2017 | +20.4% | +4.6% | +2.8% | |
| Q2 2017 | -4.2% | +1.4% | +15.3% | |
| Q1 2017 | -2.4% | -0.9% | +2.1% | |
| Q4 2016 | -6.0% | -4.5% | +0.0% | |
| Q3 2016 | -3.3% | -4.9% | -12.1% | |
| Q2 2016 | -8.6% | -13.6% | -14.5% | |
| Q1 2016 | -3.8% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -2.3% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -5.1% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2013 | -3.1% | — | — | |
| Q1 2013 | -0.8% | — | — | |
| Q4 2012 | +0.6% | — | — | |
| Q2 2012 | -0.3% | — | — | |
| Q1 2012 | -5.1% | — | — | |
| Q4 2010 | +2.9% | — | — | |
| Q4 2011 | +2.9% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | -4.1% | — | — | |
| Q3 2010 | +0.8% | — | — | |
| Q2 2010 | -0.8% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro